Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.04
-0.5300-1.92%
Post-market: 27.03-0.0100-0.04%19:59 EDT
Volume:29.12M
Turnover:794.31M
Market Cap:153.74B
PE:19.88
High:27.77
Open:27.73
Low:27.02
Close:27.57
52wk High:27.94
52wk Low:20.92
Shares:5.69B
Float Shares:5.68B
Volume Ratio:0.69
T/O Rate:0.51%
Dividend:1.72
Dividend Rate:6.36%
EPS(TTM):1.36
EPS(LYR):1.36
ROE:8.89%
ROA:5.68%
PB:1.78
PE(LYR):19.82

Loading ...

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco

Reuters
·
Mar 24

Top Premarket Decliners

MT Newswires Live
·
Mar 23

Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial

TIPRANKS
·
Mar 23

BRIEF-Pfizer Says LB6V Vaccine Candidate Was Well Tolerated With No Safety Concerns Identified At Time Of Analysis

Reuters
·
Mar 23

Pfizer: Lb6v Vaccine Candidate Was Well Tolerated With No Safety Concerns Identified at Time of Analysis

THOMSON REUTERS
·
Mar 23

Pfizer: Planning Submissions for Lb6v Vaccine Candidate to Regulatory Authorities

THOMSON REUTERS
·
Mar 23

Pfizer: Co & Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor Trial

THOMSON REUTERS
·
Mar 23

Pfizer: Vaccine Candidate Lb6v Showed More Than 70% Efficacy in Preventing Lyme Disease in People Aged Five Years & Above

THOMSON REUTERS
·
Mar 23

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Reuters
·
Mar 23

Novo Nordisk’s GLP-1 Leadership Tested By FDA Warnings And Rising Rivals

Simply Wall St.
·
Mar 22

Pfizer (PFE) Balances Trial Setback With Quiet Pipeline Push

TIPRANKS
·
Mar 21

Pfizer Recommends Shareholders Reject Tutanota Mini-Tender Offer

MT Newswires Live
·
Mar 21

Pfizer Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Mar 21

NYSE Most Active Issues

Dow Jones
·
Mar 20

Does Positive TALAPRO‑3 and FOURLIGHT‑1 Data Reframe Pfizer’s Oncology Story And Investment Case (PFE)?

Simply Wall St.
·
Mar 20

BRIEF-Talzenna Plus Xtandi Significantly Improves Radiographic Progression-Free Survival In Metastatic Prostate Cancer

Reuters
·
Mar 19

Pfizer Reports Positive Results in Prostate Cancer Study

Dow Jones
·
Mar 19

Pfizer Phase 3 TALAPRO-3 trial links TALZENNA plus XTANDI to improved rPFS in HRR-mutated mCSPC

Reuters
·
Mar 19

Pfizer - Results to Be Discussed With Global Health Authorities for Talzenna Indication Expansion

THOMSON REUTERS
·
Mar 19

Pfizer: Safety of Talzenna Plus Xtandi Was Consistent With Known Safety Profile of Each Medicine, and No New Safety Signals Were Identified

THOMSON REUTERS
·
Mar 19